Christopher M Moxham

Title: Christopher M Moxham: Innovator in Targeted Cancer Therapy

Introduction

Christopher M Moxham is a notable inventor based in Princeton Junction, NJ (US). He has made significant contributions to the field of oncology through his innovative work on targeted therapies. His research focuses on developing compounds that interact with specific cellular receptors, which can lead to more effective cancer treatments.

Latest Patents

Moxham holds a patent for "Compounds to fibroblast growth factor receptor-3 (FGFR3) and methods of treatment." This invention provides conjugates that consist of a drug moiety agent and a cell binding agent that target human fibroblast growth factor receptor 3 (FGFR3). These conjugates are designed to deliver a powerful cytotoxin inside the cell, offering significant advantages over other known conjugates. They provide targeted tumor therapy and bystander activity to neighboring cells, making them a promising option in cancer treatment.

Career Highlights

Throughout his career, Moxham has worked with prominent companies in the biotechnology sector, including Imclone LLC and Immunogen, Inc. His experience in these organizations has allowed him to refine his expertise in drug development and targeted therapies.

Collaborations

Moxham has collaborated with several professionals in his field, including Paul J Balderes and Scott W Eastman. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Christopher M Moxham is a pioneering inventor whose work in targeted cancer therapies has the potential to change the landscape of oncology treatment. His innovative approaches and collaborations continue to drive advancements in the field.